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ABSTRACT 
Dihydrofolate reductase (DHFR) plays a 
key role in folate metabolism and is a target 
molecule of methotrexate. An increase in the 
cellular expression level of DHFR is one of the 
mechanisms of tumor resistance to methotrexate. 
The present study investigated the possibility that 
adenosine-to-inosine RNA editing, which causes 
nucleotide conversion by adenosine deaminase 
acting on RNA (ADAR) enzymes, might 
modulate DHFR expression. In human breast 
adenocarcinoma-derived MCF-7 cells, 26 RNA 
editing sites were identified in the 3’-UTR of 
DHFR. Knockdown of ADAR1 decreased the 
RNA editing levels of DHFR and resulted in a 
decrease in the DHFR mRNA and protein levels, 
indicating that ADAR1 up-regulates DHFR 
expression. Using a computational analysis, miR-
25-3p and miR-125a-3p were predicted to bind to 
the non-edited 3’-UTR of DHFR but not to the 
edited sequence. The decrease in DHFR 
expression by the knockdown of ADAR1 was 
restored by transfection of antisense 
oligonucleotides for these miRNAs, suggesting 
that RNA editing-mediated up-regulation of 
DHFR requires the function of these miRNAs. 
Interestingly, we observed that the knockdown of 
ADAR1 decreased cell viability and increased the 
sensitivity of MCF-7 cells to methotrexate. 
ADAR1 expression levels and the RNA editing 
levels in the 3’-UTR of DHFR in breast cancer 
tissues were higher than those in adjacent normal 
tissues. Collectively, the present study 
demonstrated that ADAR1 positively regulates 
the expression of DHFR by editing the miR-25-
3p and miR-125a-3p binding sites in the 3’-UTR 
of DHFR, enhancing cellular proliferation and 
resistance to methotrexate.  
 
 





Dihydroforate reductase (DHFR) is a key 
enzyme in folate metabolism. DHFR catalyzes 
the reduction of dihydrofolate to tetrahydrofolate 
using NADPH as a cofactor. Since 
tetrahydrofolate is essential for de novo purine 
and thymidylate synthesis required for DNA 
synthesis, cell growth and proliferation, DHFR is 
a target of chemotherapeutic agents such as 
methotrexate and pemetrexed (1-3). The clinical 
efficacy of methotrexate is often limited by the 
acquisition of resistance in cancer cells. As 
mechanisms of methotrexate resistance, 
mutations in the DHFR gene leading to a 
decreased affinity of DHFR protein to 
methotrexate (4-6) and decreased uptake of 
methotrexate due to impaired transport (7-9) are 
known. In addition, overexpression of DHFR 
protein in methotrexate-resistant cells (10) has 
been considered. DHFR expression is regulated 
by multiple mechanisms (11), including gene 
amplification (12, 13), Sp1 and E2F1-mediated 
transcriptional up-regulation (14, 15), as well as 
microRNA (miRNA)-mediated post-
transcriptional repression (16-18). In this study, 
we sought to investigate a possibility that RNA 
editing might also underlie the regulatory 
mechanism. 
RNA editing is a post-transcriptional 
process that alters the nucleotide sequence of 
RNA transcripts. In animals, the most common 
type of RNA editing is deamination of adenosine 
(A) into inosine (I), A-to-I RNA editing (19, 20). 
Since much of the cellular machinery treats 
inosine as a guanine nucleotide, the conversion of 
nucleotides potentially changes the amino acid 
sequence, splicing, miRNA targeting, or miRNA 
maturation (21). A-to-I RNA editing is catalyzed 
by adenosine deaminases acting on RNA 
(ADAR) enzymes (22, 23). They convert 
adenosines in double-stranded RNA (dsRNA) 
structures into inosines by hydrolytic 
deamination. There are three members of the 
ADAR family in vertebrates: ADAR1, ADAR2, 
and ADAR3 (also called ADAR, ADARB1, and 
ADARB2, respectively) (24). ADAR1 and 
ADAR2 are ubiquitously expressed and have 
RNA editing activity. In contrast, there is no 
evidence to support the enzymatic activity of 
ADAR3. (25). The ADAR1 gene produces two 
protein isoforms, ADAR1 p110 (110 kDa protein) 
and ADAR1 p150 (150 kDa protein), from 
different transcription initiation sites and start 
codons. The former is constitutively expressed in 
the nucleus, whereas the latter is localized in both 
nuclear and cytoplasmic compartments and 
induced by interferon (26, 27).  
Early studies revealed that RNA editing 
plays important roles in the central nervous 
system (28). For example, glutamate receptor 
subtype A2 and 5-hydroxytryptamine receptor 
subtype 2C were known to be subjected to RNA 
editing (29-31), and the disruption of RNA 
editing in these genes leads to amyotrophic lateral 
sclerosis and Prader-Willi syndrome, respectively 
(32, 33). In these cases, A-to-I editing occurs 
within exons, changing crucial amino acids for 
protein function. Accumulating evidence has 
revealed that aberrant ADAR expression and 
disrupted RNA editing levels are associated with 
diseases including cancer, metabolic diseases, 
viral infections, autoimmune disorders and 




neurological disorders (34). Recent progress in 
next-generation sequencing with RNA-Seq has 
resulted in the identification of global RNA 
editing sites in non-coding as well as coding 
regions, supporting broader roles of RNA editing 
in the body (35, 36). Information regarding RNA 
editing sites in the transcriptome is compiled in 
databases such as RADAR, but the biological 
significance of RNA editing in humans has not 
been completely elucidated. We noticed that 
DHFR has been included in RADAR, as a target 
of RNA editing. Multiple RNA editing sites were 
identified at introns 3, 4, and 5 as well as 3’-UTR 
of DHFR mRNA in the lymphoblastoid cell line 
and brain (37, 38). However, it is uncertain 
whether the DHFR is edited or not in breast 
cancer, in which ADAR1 has been reported to 
function as an oncogene (39). In the present study, 
we investigated the possibility that RNA editing 
might modulate DHFR expression and 
subsequently affect the proliferation and 
sensitivity of breast cancer cells to methotrexate. 
 
RESULTS 
Knockdown of ADAR1 results in a 
dramatic decrease in DHFR expression in MCF-
7 Cells-The effects of knockdown of ADAR1 or 
ADAR2 on human DHFR expression in MCF-7 
cells were investigated. The siADAR1 targets 
both ADAR1 p110 and ADAR1 p150. As shown 
in Fig. 1A and B, there was a significant decrease 
in ADAR1 (both p110 and p150) and ADAR2 
protein levels by transfection of siADAR1 and 
siADAR2, respectively. Regarding the DHFR 
transcripts, four different variants (v1-v4) are 
registered in the NCBI database (Fig. 1C), and it 
is conceivable that the functional protein is 
produced only from v1 transcript. Taking 
potential effects of RNA editing within introns on 
splicing into consideration, the expression levels 
of the four DHFR transcripts in the siRNA-
transfected cells were determined. The 
knockdown of ADAR1 resulted in a significant 
decrease in the levels of all types of DHFR 
transcripts (Fig. 1D-G). In contrast, the 
knockdown of ADAR2 significantly decreased 
only the DHFR v2 mRNA level. Furthermore, a 
significant decreased in DHFR protein levels by 
siADAR1 was also observed (Fig. 1H). These 
results indicated that ADAR1 has a role in up-
regulating DHFR expression.  
ADAR1 edits the 3’-UTR of DHFR-The 
RADAR, a database for RNA editing sites, 
includes human DHFR, the transcript of which 
are subjected to RNA editing. The editing sites 
were identified in introns 3, 4, and 5 and the 3’-
UTR of DHFR in the lymphoblastoid cell line and 
brain. It is unknown whether the DHFR transcript 
is subjected to RNA editing in other tissues 
including breast. We sought to investigate 
whether the 3’-UTR, rather than introns, of 
DHFR in MCF-7 cells is subjected to RNA 
editing since ADAR1 positively regulates DHFR 
expression regardless of the transcript variants. 
We performed direct sequence analyses of the 3’-
UTR of DHFR using genomic DNA and cDNA 
from MCF-7 cells as templates. Because inosine 
is recognized as guanosine by sequence analysis, 
A-to-I RNA edited sites are identified as 
overlapping peaks of adenosine and guanosine. 
We found 26 edited sites in the 3’-UTR of DHFR 
with editing levels ranging from 2.9% to 71.4% 




(Fig. 2A and B). They were located within 
inverted Alu repeats, which can form a dsRNA 
structure, a typical target of ADAR enzymes. To 
investigate whether ADAR1 or ADAR2 enzyme 
is responsible for the RNA editing events, we 
analyzed the sequence of the DHFR cDNA from 
MCF-7 cells transfected with siADAR1 or 
siADAR2. Typical sequencing 
electropherograms of these RNA edited sites are 
shown in Fig. 2C. The RNA editing levels of all 
editing sites were significantly reduced by 
ADAR1 knockdown, but not by ADAR2 
knockdown (Fig. 2B). These results indicated that 
ADAR1 plays a critical role in editing of the 3’-
UTR of DHFR. 
RNA editing stabilizes DHFR mRNA-To 
determine whether the decrease in DHFR mRNA 
by ADAR1 knockdown is due to accelerated 
mRNA degradation, we examined the stability of 
the DHFR mRNA in the siRNA-transfected cells. 
In the presence of α-amanitin, DHFR mRNA 
level was gradually decreased. The half-life of the 
DHFR mRNA in the siControl-transfected cells 
was 28.8 hr, whereas that in siADAR1-
transfected cells was 9.4 hr (Fig. 3A). These 
results indicated to us that the non-edited DHFR 
mRNA is more unstable than edited mRNA. To 
investigate this possibility, we performed direct 
sequence analysis of cDNA from siControl-
transfected cells 6 hr, 12 hr, and 24 hr after 
treatment of -amanitin. As shown in Fig. 3B as 
a typical example (RNA editing site No. 15 and 
16), the heights of G were increased and those of 
A were decreased by treatment of α-amanitin for 
24 hr. Such changes were observed in the other 
RNA editing sites (data not shown). To evaluate 
the degradation rates of non-edited and edited 
DHFR mRNAs, their levels were calculated by 
multiplying the DHFR mRNA levels at each time 
point (Fig. 3A) by the ratio of the peak height of 
A and G, respectively, at corresponding time 
points (Fig. 3C). As shown in Fig. 3D, it was 
demonstrated that the non-edited DHFR mRNA 
was dramatically decreased by treatment of α-
amanitin for 24 hr, whereas the edited DHFR was 
not changed. Collectively, we found that DHFR 
mRNA was stabilized by ADAR1-mediated RNA 
editing. 
RNA editing of the DHFR transcript 
destroys miRNA recognition elements in the 3’-
UTR-We surmised that the decrease in extent of 
RNA editing by ADAR1 knockdown would 
augment the binding of miRNA(s) to the 3’-UTR 
of DHFR to decrease its expression, since the 3’-
UTR extensively includes binding sites for 
miRNAs, which down-regulate gene expression 
via translational repression or mRNA degradation 
(40). By using a database miRediTar, we searched 
for miRNAs that would bind to the non-edited 
sequence in the 3’-UTR of DHFR but not to 
edited sequence, considering their substantial 
expression in MCF-7 cells (41). As a result, miR-
25-3p and miR-125a-3p were raised as candidate 
miRNAs (Fig. 4A). To examine whether RNA 
editing affects the recognition of miR-25-3p and 
miR-125a-3p, we performed luciferase assays 
using reporter plasmids carrying a non-edited or 
edited microRNA recognition element (MRE) for 
miR-25-3p or miR-125a-3p. They were named 
pGL3p/MRE25(A) (non-edited MRE for miR-
25-3p), pGL3p/MRE25(G) (edited MRE for miR-
25-3p), pGL3p/MRE125(A) (non-edited MRE 




for miR-125-3p), pGL3p/MRE125(G) (edited 
MRE for miR-125-3p). The luciferase activities 
of the pGL3p/MRE25(A) and 
pGL3p/MRE125(A) plasmid were significantly 
reduced (68% and 71% of the control, 
respectively) by the overexpression of miR-25 
and miR-125a-3p, respectively, whereas the 
decrease in luciferase activities of the 
pGL3p/MRE25(G) and pGL3p/MRE125(G) 
plasmid were marginal (88% and 91% of the 
control, respectively) (Fig. 4B). Since a slight 
reduction was observed in the activities of empty 
plasmid, the decrease in activity of latter plasmids 
would likely be independent of the inserted 
fragment. Thus, it was suggested that miR-25-3p 
and miR-125a-3p recognize the non-edited 
sequences in the 3’-UTR of DHFR.  
To further confirm that siADAR1-
mediated down-regulation of DHFR is owing to 
binding of these miRNAs to the non-edited 
sequence of DHFR, overexpression or inhibition 
experiment of miRNAs was performed. When 
miR-25-3p or miR-125a-3p was co-transfected 
with siADAR1, the decrease in DHFR mRNA 
(Fig. 4C) and protein (Fig. 4D) levels by 
knockdown of ADAR1 were augmented. 
However, inhibition of these miRNA functions 
attenuated the decrease in DHFR expression by 
ADAR 1 knockdown (Fig. 4E and F). These 
results indicated that the non-edited DHFR-
specific down-regulation by miR-25-3p and miR-
125a-3p would be responsible for reduction of 
DHFR expression by ADAR1 knockdown.  
Suppression of DHFR expression by 
ADAR1 knockdown decreases cell viability and 
increases sensitivity to methotrexate of MCF-7 
cells-We noticed that the viability of MCF-7 cells 
was significantly decreased when ADAR1 was 
knocked down (Fig. 5A). Because DHFR has a 
key role in regulating the DNA synthesis by 
converting dihydrofolate into tetrahydrofolate, 
we postulated that the decrease in cell viability 
would be due to the decrease in DHFR protein 
level. To test this hypothesis, folinic acid, which 
is readily converted into tetrahydrofolate, was 
added to the siADAR1-transfected MCF-7 cells 
(42). As shown in Fig. 5B, the decreased cell 
viability by ADAR1 knockdown was partially 
restored by folinic acid treatment, suggesting that 
suppression of DHFR protein is one of the 
underlying causes of decreased cell viability by 
ADAR1 knockdown.  
Next, we investigated whether ADAR1 
knockdown increases the sensitivity of MCF-7 
cells to methotrexate because it is known that 
tumors with reduced expression of DHFR are 
more sensitive to methotrexate treatment (43, 44). 
In this experiment, the transfected siADAR1 was 
decreased to 0.5 nM to make it easier to detect the 
efficacy of methotrexate. The increase in cell 
number of siControl-transfected cells was 
decreased 48 hr and 72 hr after methotrexate 
treatment, which was further decreased by 
ADAR1 knockdown, suggesting that the 
suppression of DHFR by ADAR1 knockdown 
can increase the efficacy of methotrexate (Fig. 
5C).  
ADAR1 Expression and RNA Editing 
Levels in DHFR mRNA are Higher in Breast 
Cancer Tissues than in Normal Tissue-To 
examine the role of ADAR1 in RNA editing of 
DHFR in vivo, ADAR1 expression and RNA 




editing levels of the DHFR transcript in breast 
cancer tissues and adjacent normal tissues from 
19 patients were determined. The ADAR1 mRNA 
levels in breast cancer tissues tended to be higher 
than those in adjacent normal tissues (Fig. 6A), 
consistent with a previous report (39). Next, by 
selecting 3 samples of which ADAR1 levels in 
cancer tissue were higher than in normal tissues 
(ADAR1 expression tumor/normal ratios of 9.7, 
14.0, and 16.7) and 3 samples of which ADAR1 
levels in cancer tissues were equal to or lower 
than in normal tissues (0.1, 0.9, and 1.0), the RNA 
editing levels in the 3’-UTR of DHFR were 
evaluated. In the former samples, the RNA 
editing levels of the DHFR transcript were higher 
in cancer tissues than in adjacent normal tissues 
(Fig. 6B), but in the latter samples (Fig. 6C), this 
phenomenon was not observed. These results 
suggest that the increased expression of ADAR1 
in breast cancer contributes to hyper-editing of 
the DHFR transcript, which would result in an 
increase in DHFR expression. 
 
DISCUSSION 
It has been proposed that RNA editing 
may alter miRNA recognition (45, 46), but the 
evidence is very limited (47-49). In this study, we 
examined the possibility that RNA editing may 
regulate DHFR expression by altering 
nucleotides in miRNA binding sites in the 3’-
UTR.  
We found that ADAR1 catalyzes RNA 
editing in the 3’-UTR of DHFR in MCF-7 cells 
and breast cancer tissues (Fig. 2B, C, Fig. 6B and 
C). The identified RNA editing sites are in the 
inverted Alu repeats, which can form a perfectly 
matched dsRNA structure. This is consistent with 
a recent report showing that ADAR1, rather than 
ADAR2, is the main RNA editing enzyme for 
reversely oriented Alu repeats (50). As shown in 
Fig. 2B, knockdown of ADAR2 slightly 
increased RNA editing levels in the 3’-UTR of 
DHFR. It is known that homodimerization is 
important for the functions of both human 
ADAR1 and ADAR2, whereas 
heterodimerization between ADAR1 and 
ADAR2 has been shown to decrease editing 
activity (51). Therefore, a possible reason for the 
increase in RNA editing levels by ADAR2 
knockdown may be due to an increase in ADAR1 
homodimerization along with a decrease in 
ADAR2 heterodimerization with ADAR1.  
We found that ADAR1 knockdown 
facilitated the degradation of DHFR mRNA in 
MCF-7 cells (Fig. 3A). Supporting this result, an 
increase in the instability of non-edited DHFR 
mRNA than edited mRNA was demonstrated (Fig. 
3D), indicating that RNA editing is a critical 
factor for determining the DHFR mRNA 
degradation rate. As an underlying mechanism of 
the RNA editing-dependent regulation of DHFR 
expression, we focused on miRNA. By computer 
analysis, miR-25-3p and miR-125a-3p were 
predicted to bind to the non-edited but not edited 
DHFR (Fig. 4A). The non-edited sequence-
specific recognition by these miRNAs was 
experimentally proven by the luciferase assay 
(Fig. 4B). Through co-transfection of siADAR1 
with miRNA mimics or AsO, it was demonstrated 
that these miRNAs mediate the editing-associated 
modulation of DHFR expression (Fig. 4C-F). The 
miR-25-3p and miR-125a-3p have been reported 




to regulate Smad7 and breast cancer early onset 
gene 1 in MCF-7 cells, respectively (52, 53), 
suggesting the functional expression of these 
miRNAs in this cell lines. In addition, it has been 
reported that these miRNAs are expressed alos in 
breast cancer tissues (54, 55). Our study indicated 
that RNA editing in the 3’-UTR of DHFR would 
allow DHFR mRNA to escape from repression by 
these miRNAs, leading to an increase in DHFR 
expression in breast cancer cells. To examine 
whether the decrease in DHFR expression by 
ADAR1 knockdown was completely due to the 
function of miR-25-3p and miR-125a-3p, double 
transfection of AsOs for these miRNAs with 
siADAR1 was performed. As the result, double 
inhibition of these miRNAs could not completely 
restore the decreased DHFR expression level by 
knockdown of ADAR1 (data not shown), 
suggesting that other factors may be involved in 
this regulatory mechanism. miR-92a-3p and miR-
92b-3p may be involved because they have the 
same seed sequence with miR-25-3p. In addition 
to miRNAs, a recent study revealed that RNA 
editing within reversely oriented Alu repeats 
enables the recruitment of an RNA-binding 
protein human antigen R to the 3’-UTR to 
increase the mRNA stability of cathepsin S (50). 
It would be of interest to investigate whether such 
factors are involved in the regulation of DHFR 
expression.  
Another possible mechanism for the 
decrease in DHFR expression by ADAR1 
knockdown is induction of negative regulators 
such as miRNA for DHFR expression, because A-
to-I editing can alter the processing of miRNA, 
thereby affecting miRNA expression (56, 57). 
Further studies are warranted to explore the 
effects of RNA editing on expression levels of 
miRNAs including miR-24, miR-192 and miR-
215, which have been reported to regulate DHFR 
expression (16-18).    
By ADAR1 knockdown, the viability of 
MCF-7 cells was decreased (Fig. 5A), which is 
consistent with a previous report (39) and 
supports the oncogenic ability of ADAR1 in 
breast cancer cells. The decrease was partially 
restored by treatment with folinic acid, which can 
supply tetrahydrofolate (Fig. 5B). These results 
suggest that DHFR is likely one of the targets that 
are responsible for the oncogenic function of 
ADAR1. In addition, as shown in Fig. 5C, 
ADAR1 knockdown enhanced the sensitivity of 
MCF-7 cells to methotrexate, although the extent 
was not so dramatic (17.2% and 30.4% decrease 
in cell number by treatment with methotrexate in 
siControl- and siADAR1-transfected cells, 
respectively). A previous study has reported that 
MCF-7 is more resistant to methotrexate (IC50 
value: 114 nM) compared with the other cell lines 
(IC50 value: 6-38 nM) since the MCF-7 cells 
have mutated reduced folate career gene, leading 
to a decrease in methotrexate uptake (58). 
Thereby, we used another cell line A549, which 
has a relatively lower IC50 value of methotrexate 
(38 nM) than MCF-7, to examine the effects of 
ADAR1 knockdown on the efficiency of 
methotrexate. In accordance with the report by 
Yoon et al. (58), the reduction in cell viability of 
A549 cells by treatment with methotrexate 
(52.9% of control at 72 hr) (Fig. 7) was larger than 
that of MCF-7 cells (82.8% of control at 72 hr) 
(Fig. 5C). ADAR1 knockdown enhanced the 




sensitivity of A549 cells to methotrexate, but the 
effects (27.0% decrease: siControl+methotrexate 
versus siADAR1+methotrexate) were small 
compared with those in MCF-7 cells (22.9% 
decrease), implying a low contribution of DHFR 
to cellular toxicity of methotrexate. It has been 
reported that dihydrofolate reductase like 1, 
which is encoded by a pseudogene DHFRP4, is 
expressed and has the same function as DHFR in 
folate metabolism (59). It is possible that this 
enzyme may complement the decreased 
expression of DHFR by ADAR1 knockdown, 
producing resistance to methotrexate.  
Accumulating evidence has revealed 
that ADAR-mediated A-to-I RNA editing is 
involved in cancer development and progression. 
It is of interest to note that it differs among cancer 
types whether ADARs function as oncogenes or 
tumor suppressive genes (34). In brain tumors, 
ADAR1 and ADAR2 are down-regulated, 
leading to a global reduction in A-to-I editing, 
which is functionally required for brain tumor 
development (60). In contrast, ADAR1 has been 
reported to be up-regulated in hepatocellular 
carcinoma (61) and esophageal squamous cell 
carcinoma (62), and cell-based assays have 
revealed ADAR1 induced tumorigenic 
phenotypes in these cancer cells. More recently, it 
was revealed that ADAR1 expression and the 
editing frequency of global transcripts were 
higher in breast tumors compared with normal 
tissues (39). In agreement with the report, higher 
expression levels of ADAR1 in breast cancer 
tissues than in adjacent normal tissues was 
observed in our study, although the difference 
was not significant due to the large interindividual 
variability in the expression (Fig. 6A). The 
ADAR1 gene is located on chromosome 1q, of 
which amplification has often been observed in 
breast cancer tissues (63). Fumagalli et al. 
proposed that ADAR1 expression levels in breast 
cancer were determined in part by the extent of 
gene amplification as well as the expression of 
STAT1 (as a proxy for interferon response) (39). 
In tumor tissues with high ADAR1 expression, 
RNA editing levels of the DHFR transcript were 
higher than those in normal tissues (Fig. 6B). It is 
conceivable that the enhanced RNA editing 
would result in high DHFR expression to 
facilitate the proliferation of cancer cells. Hence, 
ADAR1-mediated regulation of DHFR would be 
an important factor in cancer development and 
progression.  
In conclusion, we found that DHFR is 
post-transcriptionally regulated through ADAR1-
mediated RNA editing, affecting cell proliferation 
and sensitivity of breast cancer cells to 
methotrexate. This study could provide new 
insights into the regulatory mechanism of DHFR 
expression and the role of RNA editing in 
methotrexate response. ADAR1 may be a 
potential anti-tumor target for use with anti-folate 
compounds including methotrexate. 
 
EXPERIMENTAL PROCEDURE 
Chemicals and reagents-Methotrexate 
hydrate and folinic acid calcium salt hydrate were 
from Tokyo Kasei (Tokyo, Japan) and Sigma-
Aldrich (St. Louis, MO), respectively. The pGL3-
promoter vector, phRL-TK vector, and Dual-
Luciferase Reporter Assay System were 
purchased from Promega (Madison, WI). 




Lipofectamine RNAiMAX, Lipofectamine 2000, 
Silencer Select siRNA for human ADAR1 
(s1007) (siADAR1), human ADAR2 (s1010) 
(siADAR2), negative control #1 (siControl) and 
miRNA mimics for miR-25-3p and miR-125a-3p 
and negative control #1 (miControl) were 
purchased from Life Technologies (Carlsbad, 
CA). Antisense locked nucleic acid/DNA 
oligonucleotides (AsO) for miR-25-3p (5’- TCA 
GTC CGA GAC AAG TGC AAT G-3’; locked 
nucleic acids are underlined), miR-125a-3p (5’-
GGC TCC CAA GAA CCT CAC CTG T-3’) and 
the negative control (5’-AGA CUA GCG GUA 
UCU UAA ACC-3’) (AsControl) were 
commercially synthesized by Gene Design 
(Osaka, Japan). RNAiso, random hexamers, and 
SYBR Premix Ex Taq were from Takara (Shiga, 
Japan). ROX was purchased from Stratagene (La 
Jolla, CA). ReverTra Ace was purchased from 
Toyobo (Osaka, Japan). All primers were 
commercially synthesized at RIKAKEN (Nagoya, 
Japan). -Amanitin was purchased from 
Calbiochem (San Diego, CA). The rabbit anti-
human DHFR polyclonal antibody (ab49881) 
was from Abcam (Cambridge, MA), and mouse 
anti-human ADAR1 monoclonal antibody (sc-
5579) and mouse anti-human ADAR2 
monoclonal antibody (sc-73408) were from Santa 
Cruz Biotechnology (Santa Cruz, CA). The rabbit 
anti-human GAPDH polyclonal antibody (IMG-
5143A) was purchased from IMGENIX (San 
Diego, CA). IRDye 680 goat anti-rabbit IgG and 
goat anti-mouse IgG were from LI-COR 
Biosciences (Lincoln, NE). Cell Counting Kit-8 
(CCK-8) was from Dojin Chemical Laboratories 
(Kumamoto, Japan). Restriction enzymes were 
from New England Biolabs (Ioswich, MA). All 
other chemicals and solvents were of the highest 
grade commercially available. 
Cell cultures-MCF-7, a human breast 
adenocarcinoma cell line, was obtained from the 
American Type Culture Collection (Manassas, 
VA). A549, a human lung carcinoma cell line, 
was obtained from the Riken Gene Bank 
(Tsukuba, Japan). The MCF-7 cells were cultured 
in DMEM (Nissui Pharmaceutical, Tokyo, Japan) 
supplemented with 0.1 mM nonessential amino 
acids (Invitrogen) and 10% FBS (Invitrogen). All 
cells were maintained at 37°C under an 
atmosphere of 5% CO2 and 95% air. 
Transfection of siRNA, miRNA mimic or 
AsO into MCF-7 Cells and preparation of cell 
homogenates and total RNA-The MCF-7 cells 
were seeded into 6-well plates and 5 nM siRNA-
Lipofectamine RNAiMAX complexes were 
added. For double transfection, 10 nM miRNA 
mimic or 10 nM AsO was co-transfected with 10 
nM siRNA into the cells. After 72 hr, the cells 
were harvested, suspended in a small amount of 
TGE buffer [10 mM Tris-HCl, 20% glycerol, and 
1 mM EDTA (pH 7.4)] and disrupted by freeze-
thawing three times. Total RNA was prepared 
using RNAiso.   
SDS-PAGE and Western blot analysis-To 
analyze DHFR (21 kDa), ADAR1 (110 and 150 
kDa), and GAPDH (36 kDa) protein levels, cell 
homogenates from MCF-7 cells were separated 
by 15%, 7.5% and 10% SDS-PAGE, respectively, 
and transferred to an Immobilon-P transfer 
membrane (Millipore, Billerica, MA). To analyze 
ADAR2 (90 kDa) protein levels, the cell 
homogenates were separated by 7.5% SDS-




PAGE and transferred to a Protran nitrocellulose 
membrane (Whatman GmbH, Dassel, Germany). 
The membranes were probed with rabbit anti-
human DHFR polyclonal, mouse anti-human 
ADAR1 monoclonal, mouse anti-human ADAR2 
monoclonal, or rabbit anti-human GAPDH 
polyclonal antibodies and the corresponding 
fluorescent dye-conjugated secondary antibodies. 
The band densities were quantified with an 
Odyssey Infrared Imaging system (LI-COR 
Biosciences). The DHFR, ADAR1 and ADAR2 
protein levels were normalized to GAPDH.  
 Real-time RT-PCR for DHFR transcript 
variants and ADAR1 mRNA-cDNA was 
synthesized from total RNA using ReverTra Ace. 
The sequences of the used primers are shown in 
Table 1. A 1-L portion of the reverse-
transcription mixture was added to a PCR mixture 
containing 10 pmol of each primer, 12.5 L of the 
SYBR Premix Ex Taq solution, and 75 nM Rox 
in a final volume of 25 L. Real-time PCR was 
performed using Mx3000P (Stratagene, La Jolla, 
CA) with the MxPro QPCR software. The PCR 
conditions for DHFR v1 and v4 were as follows: 
after an initial denaturation at 95°C for 30 s, 
amplification was performed by denaturation at 
94°C for 20 s, followed by annealing/extension at 
62°C for 20 s for 40 cycles. The PCR conditions 
for DHFR v2 and v3 were as follows: after an 
initial denaturation at 95°C for 30 s, amplification 
was performed by denaturation at 94°C for 20 s, 
followed by annealing at 53°C for 20 s and 
extension at 72°C for 20 s for 40 cycles. The PCR 
conditions for ADAR1 were as follows: after an 
initial denaturation at 95°C for 30 s, amplification 
was performed by denaturation at 94°C for 20 s, 
followed by annealing/extension at 64°C for 20 s 
for 40 cycles. The levels of DHFR variant 
transcripts were normalized to those of GAPDH 
mRNA (64). The ADAR1 mRNA levels in human 
breast cancer tissues described below were 
normalized to those of 18S rRNA (65).  
Evaluation of RNA editing levels in the 
3’-UTR of DHFR-To analyze RNA editing levels, 
direct sequencing of PCR products was 
performed. The 3’-UTR of DHFR was amplified 
by PCR using genomic DNA or cDNA as a 
template. The following primer sets for genomic 
DNA or cDNA were used to amplify the 3’-UTR 
of DHFR: the forward primer 5’-TTT ATC CAA 
CTT GAC AGT GG-3’ and the reverse primer 5’-
CTT CAC CCT TGA TTA TTT GG-3’ or the 
forward primer 5’-AGC TGC TCT ATA GCA 
AGT CT-3’ and the reverse primer 5’-CTT CAC 
CCT TGA TTA TTT GG-3’. The PCR mixture 
consists of the genomic DNA or cDNA, 1×PCR 
buffer, 0.4 µM of each primer and 0.5 U of Gflex 
polymerase (TAKARA, Shiga, Japan) in a final 
volume of 25 µL. After an initial denaturation at 
94°C for 1 min, amplification was performed with 
denaturation at 98°C for 10 s, annealing at 54°C 
for 15 s, and extension at 72°C for 70 s (genomic 
DNA) or 40 s (cDNA) for 35 cycles, followed by 
a final extension at 72°C for 5 min. The PCR 
products were subjected to electrophoresis using 
a 0.8% agarose gel. Control experiments without 
the reverse transcriptase were conducted to verify 
that the amplified products were from the reverse-
transcribed cDNA rather than from contaminating 
genomic DNA. Specific products were purified 
and subjected to direct sequencing. The extent of 
editing was represented as a percentage 




calculated from the ratio of the peak height of ‘G’ 
over the sum of the peak heights of ‘G’ and ‘A’ in 
the sequencing electropherograms. 
Evaluation of the stability of DHFR 
mRNA-MCF-7 cells were transfected with siRNA, 
as described above. After 36 hr, the cells were 
treated with 10 μg/mL α-amanitin, an inhibitor of 
transcription. Total RNA was prepared 0, 6, 12 
and 24 hr later. The DHFR mRNA level was 
determined by real-time RT-PCR, as described 
above. 
Reporter plasmids construction-A 
fragment from +1901 to +2153 containing the 
microRNA recognition elements (MRE) for miR-
25-3p (MRE25) and that from +2443 to +2569 
containing the MRE for miR-125a-3p (MRE125) 
of the non-edited 3’-UTR of DHFR were 
amplified by PCR using MCF-7 genomic DNA as 
a template and were inserted into the pGL3p 
vector at the Xba I site downstream of the 
luciferase gene. The constructed luciferase 
reporter plasmids were termed 
pGL3p/MRE25(A) and pGL3p/MRE125(A), 
respectively. Two corresponding fragments were 
also amplified by PCR using MCF-7 cDNA as a 
template and were inserted into the pGL3p vector. 
A clone containing MRE25 with edited 
nucleotides (guanosines) at site No. 1, 2, 3, 5, 7, 
8, 10 and 11 and that contained MRE125 with 
guanosines at No. 16, 17, 18, 19, and 20 (refer to 
Fig. 2A) was selected and used as reporter 
plasmids (pGL3p/MRE25(G) and 
pGL3p/MRE125(G), respectively). By direct 
sequence analysis, we confirmed that RNA 
editing events did not occur in the transcripts of 
reporter genes in MCF-7 cells transfected with 
pGL3p/MRE25(A) or pGL3p/MRE25(G). 
Luciferase assay-MCF-7 cells were 
transiently transfected with various pGL3 
luciferase reporter plasmids and the phRL-TK 
plasmid. Briefly, the day before transfection, the 
cells were seeded into 24-well plates. After 24 hr, 
the cells were transfected with 190 ng pGL3p 
plasmid, 10 ng phRL-TK plasmid, and 30 nM 
miR-25-3p, miR-125a-3p mimic or miControl 
using Lipofectamine 2000. After incubation for 
48 h, the cells were resuspended in passive lysis 
buffer, and luciferase activity was measured on a 
luminometer using the Dual-Luciferase Reporter 
Assay System.  
Assessment of cell viability-To evaluate 
cell viability, a WST-8 (2-(2-methoxy-4-
nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-
disulfophenyl)-2H-tetrazolium monosodium salt) 
assay, which is a modified MTT assay, was 
performed. MCF-7 cells were transfected with 5 
nM siRNA as described above and incubated for 
72 hr. The viability of siADAR1-transfected 
MCF-7 cells was evaluated in the presence or 
absence of 200 μM folinic acid. The effects of 
ADAR1 knockdown on the sensitivity of MCF-7 
or A549 cells to methotrexate were investigated 
as follows; MCF-7 or A549 cells were transfected 
with 0.5 nM siRNA. After 24 hr, the cells were 
treated with 50 nM methotrexate for 24, 48 and 
72 hr. CCK-8 reagent was then added, and the 
absorbance of the medium at 450 nm was 
measured. The percent cell viability was 
calculated by comparing the absorbance of the 
treated cells with the control cells. 
Human breast cancer and adjacent 
normal tissues-Breast cancer and adjacent normal 




tissues obtained as surgical samples from 19 
Japanese patients (42 - 77 years old, did not 
undergo chemotherapy) with primary breast 
carcinoma (66) were used. This study was 
approved by the Ethics Committee of Kanazawa 
University (Kanazawa, Japan). Written informed 
consent was obtained from patients. The samples 
were obtained immediately after resection, 
divided into breast cancer and adjacent normal 
tissues, and immediately frozen with liquid 
nitrogen. The samples were stored at -80°C until 
use. Total RNA was prepared using RNAiso. 
Statistical analyses-Statistical 
significance was determined by analysis of 
variance followed by Dunnett’s multiple 
comparisons test or Tukey’s method test. The 
comparison of two groups was performed using 
an unpaired, two-tailed Student’s t-test. 
Correlation analyses were performed by 
Spearman’s rank method. A value of P < 0.05 was 
considered statistically significant. 
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The abbreviation used are: ADAR, adenosine deaminase acting on RNA; AsO, antisense locked nucleic 
acid/DNA oligonucleotides; A-to-I, adenosine-to-inosine; DHFR, Dihydrofolate reductase; dsRNA, 




FIGURE. 1. Effects of ADAR1 or ADAR2 knockdown on DHFR expression levels in MCF-7 cells. 
ADAR1 p110 and ADAR1 p150 protein (A), ADAR2 protein (B) in MCF-7 cells 72 hr after transfection 
with 5 nM siADAR1, siADAR2, or siControl were determined by Western blotting and were 
normalized to GAPDH shown in Fig. 1H. (C) Human DHFR transcript variants (v1-v4) are 




schematically represented. Open rectangles indicate exons. DHFR v1 (D), v2 (E), v3 (F), v4 (G) mRNA, 
and DHFR protein (H) levels in MCF-7 cells 72 hr after transfection with 5 nM siADAR1, siADAR2, 
or siControl were determined and were normalized to GAPDH. The Ct values of v1, v2, v3 and v4 in 
siControl-transfected MCF-7 cells were 21.4, 25.2, 28.9 and 29.9, respectively. The values represent 
the levels relative to the siControl. Each column represents the mean ± SD of three independent 
experiments. The values are expressed relative to the siControl. Each point represents the mean ± SD 
(n =3). *P < 0.05, **P < 0.01 and ***P < 0.001. 
 
FIGURE. 2. Effects of ADAR1 or ADAR2 knockdown on RNA editing levels in the 3’-UTR of DHFR. 
(A) Human DHFR v1 mRNA and RNA editing sites in the 3’-UTR of DHFR are schematically 
represented. Open arrows indicate the direction of the Alu elements. The nucleotide numbering refers 
to the 5’ end of the mRNA as 1. Vertical arrows show the RNA editing sites, numbered as 1-26 from 5’ 
to 3’. (B) RNA editing levels in the 3’-UTR of DHFR in MCF-7 cells 72 hr after transfection with 5 nM 
siADAR1, siADAR2, or siControl. The editing level is reported as a percentage, which was calculated 
by dividing the peak height of ‘G’ by the sum of the peak heights of ‘G’ and ‘A’ in the electropherograms, 
resulting from direct sequencing of PCR amplicons that used cDNA from these cells as a template. (C) 
Representative electropherograms from direct sequencing that used genomic DNA and cDNA from 
MCF-7 cells as a template. Each column represents the mean ± SD of three independent experiments. 
*P < 0.05, **P < 0.01 and ***P < 0.001. 
 
FIGURE. 3. Effects of RNA editing on DHFR mRNA stability. (A) MCF-7 cells 36 hr after transfection 
with 5 nM siADAR1 or siControl were treated with 10 μg/ml of α-amanitin. Total RNA was prepared 
after 0, 6, 12 and 24 hr. The DHFR mRNA levels were determined using real-time RT-PCR. The DHFR 
mRNA levels at time 0 (the time of addition of α-amanitin) in each treatment were assigned 100%. Each 
column represents the mean ± SD of three independent experiments. *P < 0.05 and **P < 0.01 
compared with siControl. (B) Representative electropherograms from the direct sequencing that used 
cDNA from -amanitin-treated MCF-7 cells as a template. (C and D) The expression levels of DHFR 
mRNA which is non-edited or edited in each editing sites were calculated by multiplying DHFR mRNA 
expression by the ratio of the peak height of ‘A’ or ‘G’, respectively, in the electropherograms resulting 
from the direct sequencing of PCR amplicons that used cDNA from these cells as a template. The 
amounts of total DHFR mRNA at time 0 (the time of addition of α-amanitin) in each treatment were 
assigned 100%. Each point represents the mean of three independent experiments.  
 
FIGURE. 4. Role of miR-25-3p and miR-125a-3p in ADAR1-dependent regulation of DHFR in MCF-
7 cells. (A) Human DHFR mRNA, and the predicted miRNA recognition elements (MREs) of miR-25-
3p and miR-125a-3p (termed MRE25 and MRE125, respectively) in non-edited DHFR mRNA are 




schematically represented. The numbering denotes the 5’ end of the mRNA as 1. Open arrows indicate 
the direction of the Alu elements. Bold letters represent seed sequences. RNA editing sites are shown 
by numbered (refer to fig. 2A) arrows. (B) Luciferase assay using plasmids containing a fragment of the 
3’-UTR of DHFR. MCF-7 cells were transfected with the reporter plasmids (190 ng) along with the 
phRL-TK plasmid (10 ng) and 30 nM miR-25-3p, miR-125a-3p mimic or miControl. Firefly luciferase 
activity for each construct was normalized to Renilla luciferase activity. The values are expressed 
relative to the pGL3-p plasmid. DHFR mRNA (C and E) and protein (D and F) levels in MCF-7 cells 
72 hr after co-transfection with 10 nM siRNA (siADAR1 or siControl) and 10 nM miRNA mimic (miR-
25-3p, miR-125a-3p mimic or miControl) (C and D) or co-transfection with 10 nM siRNA and 10 nM 
AsO (As-miR-25-3p, As-miR-125a-3p, or AsControl) (E and F) were determined by real time PCR or 
Western blot analysis and were normalized to GAPDH. The values are expressed relative to the control. 
Each column represents the mean ± SD of three independent experiments. *P < 0.05, **P < 0.01 and 
***P < 0.001.     
 
FIGURE. 5. Effects of ADAR1-dependent regulation of DHFR expression on viability and sensitivity 
of MCF-7 cells to methotrexate. (A) The viability of MCF-7 cells 72 hr after transfection with 5 nM 
siADAR1, siADAR2 and siControl. The values are expressed relative to the siControl. (B) The viability 
of siADAR1-transfected MCF-7 cells incubated for 72 hr in the presence of 200 M folinic acid. The 
values are expressed relative to the siControl. (C) MCF-7 cells 24 hr after transfection with 0.5 nM 
siADAR1 or siControl were treated with 50 nM methotrexate. After 0, 24, 48 and 72 hr, the cell number 
was evaluated by the WST-8 assay. The values are expressed relative to 0 hr. Each column and data 
point represents the mean ± SD of three independent experiments. *P < 0.05 **P < 0.01 and ***P < 
0.001. 
 
FIGURE. 6. Expression levels of ADAR1 mRNA and RNA editing levels in the 3’-UTR of DHFR in 
human breast cancer tissues. (A) Expression levels of ADAR1 mRNA in breast cancer tissues and 
adjacent normal tissues obtained from 19 patients were determined by real-time RT-PCR. The 
expression levels were normalized to the 18S rRNA level. Data represent the mean of two independent 
experiments. The values are expressed relative to the sample with the lowest levels. Horizontal bars 
represent the mean. The RNA editing levels in the 3’-UTR of DHFR in breast cancer tissues of which 
ADAR1 expression are higher than (No. 1-3) (B) and equal to or lower than (No. 4-6) (C) in adjacent 
normal tissues. The editing level is represented as a percentage, which was calculated by dividing the 
peak height of ‘G’ by the sum of peak heights of ‘G’ and ‘A’ in the sequencing electropherograms. Each 
column represents the mean of two independent experiments. *P < 0.05 and **P < 0.01. 
 
FIGURE. 7. Effects of ADAR1-dependent regulation of DHFR expression on sensitivity of A549 cells 




to methotrexate. A549 cells 24 hr after transfection with 0.5 nM siADAR1 or siControl were treated 
with 50 nM methotrexate. After 0, 24, 48 and 72 hr, the cell number was evaluated by the WST-8 assay. 
The values are expressed relative to 0 hr. Each column and data point represents the mean ± SD of three 
independent experiments. *P < 0.05 **P < 0.01 and ***P < 0.001. 
  




Table 1. Primers for real time RT-PCR  
Target gene  Accession No. Primer Sequence (5’ to 3’) 
DHFR v1 NM_000791 
Forward  TCC AGA GAA TGA CCA CAA CC 
Reverse  ACG TGT CAC TTT CAA AGT CT 
DHFR v2 NM_001290354 
Forward TGG CCA CCG CTC AGG TAA AC 
Reverse  GTG ATT CAT GGC TTC CTT AT 
DHFR v3 NM_001290357 
Forward TCC AGA GAA TGA CCA CAA CC 
Reverse GGG TGA TTC ATG GCT TCT TG 
DHFR v4 NR_110936 
Forward TGG CCA CCG CTC AGG TAA AC 
Reverse AGA ACA CCT GGG TAT CTT AT 
ADAR1 NM_001025107 
Forward GCT TGG GAA CAG GGA ATC G 
Reverse  CTG TAG AGA AAC CTG ATG AAG CC  
GAPDH NM_002046 
Forward CCA GGG CTG CTT TTA ACT C 
Reverse GCT CCC CCC TGC AAA TGA 
18S rRNA NR_003286 
Forward GGC CCT GTA ATT GGA ATG AGT C 
Reverse GAC ACT CAG CTA AGA GCA TCG 
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